Compare Ginkgo Bioworks Holdings Inc (DNA) vs Plby Group Inc (PLBY) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Ginkgo Bioworks Holdings Inc vs Plby Group Inc — how do they compare? Ginkgo Bioworks Holdings Inc trades at $12.95 (market cap $763.64M), while Plby Group Inc trades at $0.98 (market cap $118.21M). The key difference: Ginkgo Bioworks Holdings Inc is far larger — about 6.5× Plby Group Inc's market cap, and Ginkgo Bioworks Holdings Inc is trading nearer its 52-week high, Plby Group Inc nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Ginkgo Bioworks Holdings Inc for 7 Days and Plby Group Inc for 24 Days on average.
| DNA | PLBY | |
|---|---|---|
Market Cap | $763.64M | $118.21M |
Volume | 3,204,177 | 919,783 |
Sector | Health | Consumer Cyclical |
52-Week High | $15.83 | $2.71 |
52-Week Low | $5.48 | $0.99 |
Typical Hold Time | 7 Days | 24 Days |
Enterprise Value | $865.59M | $263.80M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Ginkgo Bioworks (DNA) trades at $13.04, up 13.69% in the last session, with a bullish technical signal from moving averages. The company maintains strong gross margins at 68.04% but faces significant losses with a -219.6% net income margin. Recent developments include a $17.5M ARPA-H subcontract for RNA medicine manufacturing and partnerships expanding genetic testing distribution.
While technical momentum appears positive, fundamental challenges persist with substantial cash burn and declining revenue projections. Analyst sentiment is divided equally between buy, hold, and sell ratings. Investment opportunity lies in the company's strategic partnerships and government contracts, balanced against ongoing profitability concerns and competitive pressures in biotech.
PLBY Group trades at $0.98, down 3.66% today, with a bearish technical signal from moving averages and oscillators. The company shows improving fundamentals with revenue stabilizing around $121 million and narrowing losses from -$278M in 2022 to -$13M in 2025. Recent leadership appointments signal strategic growth initiatives, while analyst consensus remains strongly positive with 75% buy ratings.
The outlook suggests cautious optimism as PLBY transitions toward profitability, projected to reach net income of $283,000 in 2026. Key risks include high debt levels with 59.52% debt-to-asset ratio and persistent negative shareholder equity. The stock offers potential upside if turnaround execution succeeds, but remains vulnerable to operational challenges and market sentiment shifts.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Ginkgo Bioworks Holdings Inc
Ginkgo Bioworks is a leading horizontal platform for cell programming. It uses advanced automation and software to design custom organisms for customers across diverse industries, including food, agriculture, and pharma.
Read more on DNA →About Plby Group Inc
PLBY Group Inc is a pleasure and leisure company. The company's segment includes Licensing, Direct-to-Consumer, and Digital Subscriptions and Content. It generates maximum revenue from the Direct-to-Consumer segment. Direct-to-Consumer operations include consumer products sold through third-party retailers or online direct-to-customer. Geographically, it derives a majority of revenue from the United States.
Read more on PLBY →
